<p>分析師們可能對 <strong>Blue Jet Healthcare Limited</strong> (NSE:BLUEJET) 的預期過於樂觀，因為該公司在上週發佈季度業績時未能達到預期。不幸的是，Blue Jet Healthcare 的盈利嚴重失利。收入為 ₹19 億，低於預期的 18%，法定每股收益為 ₹2.32，低於預期 35%。在業績公佈後，分析師們更新了他們的盈利模型，瞭解他們是否認為公司的前景發生了重大變化，或者一切如常，將是很有意義的。因此，我們收集了最新的業績後法定共識預期，以瞭解明年可能會發生什麼。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前投資。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1676807750-earnings-and-revenue-growth-1-dark-2/1771378630409?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1676807750-earnings-and-revenue-growth-1-dark-2/1771378630409"/></p>
<p>NSEI:BLUEJET 收益和收入增長 2026 年 2 月 18 日</p>
<p>考慮到最新的業績，Blue Jet Healthcare 八位分析師的共識預測是 2027 年收入為 ₹131 億。這反映出與過去 12 個月相比，收入有顯著的 25% 增長。法定每股收益預計將上升 6.9%，達到 ₹18.09。在這份盈利報告之前，分析師們曾預測 2027 年收入為 ₹148 億，每股收益 (EPS) 為 ₹22.52。看起來在這些結果公佈後，市場情緒大幅下降，收入預期被大幅下調，每股收益數字也大幅下降。</p>
<p>查看我們對 Blue Jet Healthcare 的最新分析</p>
<p>共識目標價下降了 30%，降至 ₹499，疲軟的盈利前景顯然導致了估值預期的下降。然而，這並不是我們可以從這些數據中得出的唯一結論，因為一些投資者在評估分析師目標價時也喜歡考慮預期的差異。目前，最樂觀的分析師將 Blue Jet Healthcare 的每股價值定為 ₹835，而最悲觀的則定為 ₹330。在這種情況下，我們可能會對分析師的預測賦予較少的價值，因為如此廣泛的預期範圍可能意味着該業務的未來難以準確估值。考慮到這一點，我們不會過於依賴共識目標價，因為這只是一個平均值，分析師們顯然對該業務有着截然不同的看法。</p>
<p>當然，另一種看待這些預測的方法是將其與行業本身進行對比。從最新的預估來看，Blue Jet Healthcare 的增長率預計將顯著加快，預計到 2027 年的年化收入增長率為 19%，明顯快於過去五年 16% 的歷史增長率。與同一行業的其他公司相比，後者預計年收入增長 10%。考慮到收入的加速增長，顯然 Blue Jet Healthcare 的增長速度預計將遠快於其行業。</p>
<h2>結論</h2>
<p>最大的問題是分析師們下調了每股收益預期，這表明 Blue Jet Healthcare 可能面臨業務阻力。不幸的是，他們也下調了收入預期，但最新的預測仍然暗示該業務將比更廣泛的行業增長得更快。此外，分析師們還下調了他們的目標價，表明最新消息導致了對該業務內在價值的更大悲觀情緒。</p>
<p>話雖如此，公司的盈利長期軌跡遠比明年的情況更為重要。我們對 Blue Jet Healthcare 的預測一直延續到 2028 年，您可以在我們的平台上免費查看。</p>
<p>您還可以查看我們對 Blue Jet Healthcare 董事會和首席執行官薪酬及經驗的分析，以及公司內部人士是否在購買股票。</p>
<h3>估值複雜，但我們在這裏為您簡化。</h3>
<p>通過我們的詳細分析，發現 Blue Jet Healthcare 是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易及其財務狀況。</strong></p>
<p>訪問免費分析</p>

<p>藍天醫療有限公司（NSE:BLUEJET）公佈了令人失望的季度業績，收入為 19 億印度盧比，比預期低 18%，每股收益為 2.32 印度盧比，低於預期 35%。在此次業績失利後，分析師們已修訂了他們的預測，預計 2027 年的收入將達到 131 億印度盧比，增長 25%，但每股收益預計僅增長 6.9%，達到 18.09 印度盧比。共識目標價已下調 30%，至 499 印度盧比，反映出市場情緒的下降。儘管評級下調，藍天醫療預計將以高於行業平均水平的速度增長，預計到 2027 年年均收入增長 19%</p>

<p>The analysts might have been a bit too bullish on <strong>Blue Jet Healthcare Limited</strong> (NSE:BLUEJET), given that the company fell short of expectations when it released its quarterly results last week. Unfortunately, Blue Jet Healthcare delivered a serious earnings miss. Revenues of ₹1.9b were 18% below expectations, and statutory earnings per share of ₹2.32 missed estimates by 35%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.</p>
<div class="lb-trans"><p>分析師們可能對 <strong>Blue Jet Healthcare Limited</strong> (NSE:BLUEJET) 的預期過於樂觀，因為該公司在上週發佈季度業績時未能達到預期。不幸的是，Blue Jet Healthcare 的盈利嚴重失利。收入為 ₹19 億，低於預期的 18%，法定每股收益為 ₹2.32，低於預期 35%。在業績公佈後，分析師們更新了他們的盈利模型，瞭解他們是否認為公司的前景發生了重大變化，或者一切如常，將是很有意義的。因此，我們收集了最新的業績後法定共識預期，以瞭解明年可能會發生什麼。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前投資。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1676807750-earnings-and-revenue-growth-1-dark-2/1771378630409" alt="" original-src="https://images.simplywall.st/asset/chart/1676807750-earnings-and-revenue-growth-1-dark-2/1771378630409"/></p>
<p>NSEI:BLUEJET Earnings and Revenue Growth February 18th 2026</p>
<div class="lb-trans"><p>NSEI:BLUEJET 收益和收入增長 2026 年 2 月 18 日</p>
</div><p>Taking into account the latest results, the consensus forecast from Blue Jet Healthcare's eight analysts is for revenues of ₹13.1b in 2027. This reflects a substantial 25% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 6.9% to ₹18.09. Before this earnings report, the analysts had been forecasting revenues of ₹14.8b and earnings per share (EPS) of ₹22.52 in 2027. It looks like sentiment has declined substantially in the aftermath of these results, with a real cut to revenue estimates and a substantial drop in earnings per share numbers as well.</p>
<div class="lb-trans"><p>考慮到最新的業績，Blue Jet Healthcare 八位分析師的共識預測是 2027 年收入為 ₹131 億。這反映出與過去 12 個月相比，收入有顯著的 25% 增長。法定每股收益預計將上升 6.9%，達到 ₹18.09。在這份盈利報告之前，分析師們曾預測 2027 年收入為 ₹148 億，每股收益 (EPS) 為 ₹22.52。看起來在這些結果公佈後，市場情緒大幅下降，收入預期被大幅下調，每股收益數字也大幅下降。</p>
</div><p>View our latest analysis for Blue Jet Healthcare</p>
<div class="lb-trans"><p>查看我們對 Blue Jet Healthcare 的最新分析</p>
</div><p>The consensus price target fell 30% to ₹499, with the weaker earnings outlook clearly leading valuation estimates. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Blue Jet Healthcare at ₹835 per share, while the most bearish prices it at ₹330. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.</p>
<div class="lb-trans"><p>共識目標價下降了 30%，降至 ₹499，疲軟的盈利前景顯然導致了估值預期的下降。然而，這並不是我們可以從這些數據中得出的唯一結論，因為一些投資者在評估分析師目標價時也喜歡考慮預期的差異。目前，最樂觀的分析師將 Blue Jet Healthcare 的每股價值定為 ₹835，而最悲觀的則定為 ₹330。在這種情況下，我們可能會對分析師的預測賦予較少的價值，因為如此廣泛的預期範圍可能意味着該業務的未來難以準確估值。考慮到這一點，我們不會過於依賴共識目標價，因為這只是一個平均值，分析師們顯然對該業務有着截然不同的看法。</p>
</div><p>Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Blue Jet Healthcare's rate of growth is expected to accelerate meaningfully, with the forecast 19% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 16% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 10% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Blue Jet Healthcare is expected to grow much faster than its industry.</p>
<div class="lb-trans"><p>當然，另一種看待這些預測的方法是將其與行業本身進行對比。從最新的預估來看，Blue Jet Healthcare 的增長率預計將顯著加快，預計到 2027 年的年化收入增長率為 19%，明顯快於過去五年 16% 的歷史增長率。與同一行業的其他公司相比，後者預計年收入增長 10%。考慮到收入的加速增長，顯然 Blue Jet Healthcare 的增長速度預計將遠快於其行業。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>結論</h2>
</div><p>The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Blue Jet Healthcare. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.</p>
<div class="lb-trans"><p>最大的問題是分析師們下調了每股收益預期，這表明 Blue Jet Healthcare 可能面臨業務阻力。不幸的是，他們也下調了收入預期，但最新的預測仍然暗示該業務將比更廣泛的行業增長得更快。此外，分析師們還下調了他們的目標價，表明最新消息導致了對該業務內在價值的更大悲觀情緒。</p>
</div><p>With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Blue Jet Healthcare going out to 2028, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>話雖如此，公司的盈利長期軌跡遠比明年的情況更為重要。我們對 Blue Jet Healthcare 的預測一直延續到 2028 年，您可以在我們的平台上免費查看。</p>
</div><p>You can also see our analysis of Blue Jet Healthcare's Board and CEO remuneration and experience, and whether company insiders have been buying stock.</p>
<div class="lb-trans"><p>您還可以查看我們對 Blue Jet Healthcare 董事會和首席執行官薪酬及經驗的分析，以及公司內部人士是否在購買股票。</p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值複雜，但我們在這裏為您簡化。</h3>
</div><p>Discover if Blue Jet Healthcare might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通過我們的詳細分析，發現 Blue Jet Healthcare 是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易及其財務狀況。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>訪問免費分析</p>
</div>

盈利未達預期：Blue Jet Healthcare Limited 的每股收益低於預期 35%，分析師正在調整他們的預測